Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) has been assigned an average rating of “Reduce” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $2.76.
A number of research firms recently weighed in on DNA. The Goldman Sachs Group reduced their price target on Ginkgo Bioworks from $0.80 to $0.30 and set a “sell” rating for the company in a report on Tuesday, July 9th. William Blair lowered Ginkgo Bioworks from a “market perform” rating to an “underperform” rating in a research report on Friday, May 10th. BTIG Research lifted their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the company a “sell” rating in a research note on Friday, August 23rd. Finally, Morgan Stanley reduced their price objective on shares of Ginkgo Bioworks from $2.00 to $1.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 15th.
Check Out Our Latest Research Report on DNA
Institutional Trading of Ginkgo Bioworks
Ginkgo Bioworks Stock Performance
Shares of Ginkgo Bioworks stock opened at $7.08 on Friday. The firm has a 50-day simple moving average of $1.53 and a two-hundred day simple moving average of $1.16. Ginkgo Bioworks has a fifty-two week low of $7.03 and a fifty-two week high of $98.60.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
- Five stocks we like better than Ginkgo Bioworks
- Short Selling: How to Short a Stock
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- Investing in Construction Stocks
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.